In this randomised, double-blind clinical trial in patients with mild to moderate AD taking an acetylcholinesterase inhibitor, 2,000 international units (IUs) a day of α-tocopherol for a mean duration of 2.3 years, resulted in slower functional decline compared to the placebo (43). This evidence concerns the gene ACHE and Alzheimer disease.